Biomedtracker and Evaluate Ltd Pharma are available via Snowflake. Access real-time tracking and analysis of the drug development pipeline and navigate the complex commercial, clinical, and regulatory landscape with precision: https://ow.ly/tqgS50ThuRw.
About us
Citeline powers a full suite of complementary business intelligence offerings to meet the evolving needs of health care professionals to accelerate the connection of treatments to patients and patients to treatments. These patient-focused solutions and services deliver and analyze data used to drive clinical, commercial and regulatory-related decisions and create real-world opportunities for growth. Our global teams of analysts, journalists and consultants keep their fingers on the pulse of the pharmaceutical, biomedical and medtech industries, covering it all with expert insights: key diseases, clinical trials, drug R&D and approvals, market forecasts and more.
- Website
-
https://www.citeline.com/
External link for Citeline
- Industry
- Information Services
- Company size
- 501-1,000 employees
- Headquarters
- New York, New York
- Type
- Privately Held
Locations
-
Primary
Get directions
New York, New York, US
-
Get directions
London, City of London, GB
Employees at Citeline
Updates
-
As this PharmaVoice article notes, with the Trump administration preparing to take office, the Biosecure Act is in limbo. The bill would require US companies to sever contracts with some Chinese research organizations. See what Pink Chief Editor in Chief Nielsen Hobbs predicts about the chance of the bill's passage.
-
In an article on AstraZeneca’s Farxiga blockbuster drug, PharmaVoice quotes Daniel Chancellor, Director of Thought Leadership at Norstella, Citeline's parent company: https://ow.ly/sCkr50TMSAl. The article also references Citeline’s “Billion Dollar Blueprint: The Journey to Blockbuster Status” report: https://ow.ly/RvuY50TMSAm. #BlockBusterDrugs #PharmaTrends #DrugDevelopment
-
-
Inform your strategic decisions with unparalleled access to worldwide pharmaceutical regulatory affairs and compliance-related intelligence with Pink Sheet! Start your free trial: https://ow.ly/Kjis50SyJrl. #Pharma #PharmaceuticalIndustry #PharmaRegulatory
-
Have you tried the all-new Citeline News and Insights app? Access all your favorite award-winning publications, all in one place. Download the app today: https://ow.ly/yuPw50SAjV7. (Available on the App Store and Google Play.)
-
NEW! IQVIA Biotech reveals the key strategies for exploring novel investigational agents and achieving high performance trials: https://ow.ly/B6Xh50Uajit. To ensure success in hematologic oncology clinical trials, biotech companies must have a deep understanding of the advancing treatment landscape and clinical best practices.
-
-
Not all solutions are created equal—choosing the right one can help you reach enrollment goals faster and gain valuable insights into trial performance: https://ow.ly/aNle50TKK5g.
-
-
Discover the physiology behind the facial divots many find irresistible, now on the PrimalBlog: https://ow.ly/y9CA50UcNbM from Primal Pictures 3D Anatomy & Physiology / Anatomy.tv. #PrimalBlog #AnatomyEducation #AnatomyStudy
-
-
The Future of Sustainable Packaging Is Here! 🌍 Download the eBook: https://ow.ly/Narw50TVuEH. Our latest eBook explores how the consumer health industry is stepping up to tackle the environmental challenges of plastic waste. Curious about what’s next? Download your copy today and discover how leaders like Haleon and Sanofi are driving change with sustainable alternatives to traditional blister packs, regulatory insights, and more. ➡️ https://ow.ly/Narw50TVuEH #Sustainability #HealthcarePackaging #PlasticFree #GreenFuture #HBWInsight
-
As this PharmaVoice article notes, with the Trump administration preparing to take office, the Biosecure Act is in limbo. The bill would require US companies to sever contracts with some Chinese research organizations. See what Pink Chief Editor in Chief Nielsen Hobbs predicts about the chance of the bill's passage.